| Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study AG Singal, NE Rich, N Mehta, A Branch, A Pillai, M Hoteit, M Volk, ... Gastroenterology 156 (6), 1683-1692. e1, 2019 | 168 | 2019 |
| Direct-acting antiviral treatment of acute hepatitis C virus infections S Misra, DT Dieterich, B Saberi, T Kushner Expert Review of Anti-infective Therapy 16 (8), 599-610, 2018 | 8 | 2018 |
| HCC SURVEILLANCE AND TUMOR DOUBLING TIMES IN A HIGH-RISK POPULATION STARTING DIRECT ACTING DRUGS FOR CHRONIC HEPATITIS C B Wyatt, PV Perumalswami, S Lewis, S Misra, K Patel, A Mageras, ... HEPATOLOGY 70, 533A-533A, 2019 | | 2019 |
| An update on the management of hepatitis C virus and human immunodeficiency virus co-infection B Tolentino, RR Singh, S Misra, DT Dieterich, D Sarpel Future Virology 14 (3), 185-195, 2019 | | 2019 |
| Hepatocellular Carcinoma Screening Rates in Patients Cured of Hepatitis C with Direct Acting Antiviral Drugs Are Lower Than Recommended and Correlate with Indicators of More … BE Wyatt, S Lewis, S Misra, L Jandorf, PV Perumalswami, AD Branch HEPATOLOGY 68, 835A-836A, 2018 | | 2018 |
| The Protective Effect of HCV Cure on HCC Risk May be over-Estimated in Patients with Advanced Liver Disease AD Branch, S Lewis, B Wyatt, E Doyle, JC Sung, S Misra, F Eng, C Bosh, ... HEPATOLOGY 68, 538A-539A, 2018 | | 2018 |
| Direct-acting antiviral therapy significantly reduces early HCC recurrence: A multicenter us cohort study. AG Singal, N Mehta, NE Rich, C Murphy, AD Branch, AA Pillai, MA Hoteit, ... | | 2018 |
| Neutrophil-to-lymphocyte ratio and decreased liver volume indicate increased hepatocellular carcinoma risk after hepatitis C cure SK Misra, JF Crismale, B Wyatt, EH Doyle, RK Sefcik, SC Lewis, ... HEPATOLOGY 66, 844A-845A, 2017 | | 2017 |
